Press Releases

Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
Bioxytran announced today the preprint in ResearchGate entitled “Association of Rapid Shingles Lesion Clearance and Regression of Herpes Zoster Neuralgia in Case Study Using Topical Galectin-3 Antagonism” showed a time lapsed clearance of the shingles lesions using a topical Galectin-3 antagonist.
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
BIOXYTRAN announced that the first patients have been treated with ProLectin-M in its dose optimization trial. ProLectin-M is intended to become a first line treatment for standard risk COVID-19 patients, but based on the broad-spectrum in vitro discovery could easily expand to upper respiratory tract infections.
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
BIXT announces that the U.S Patent and Trademark Office (USPTO) has published the Company’s patent application WO2023178228A1 Lectin-binding carbohydrates for treating viral infections. The pending patent covers broad claims about the use of hundreds of combinations of antiviral complex carbohydrate drugs to treat over 60 named viruses.
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
New article showcasing the significant reduction of viral load in COVID-19, influenza (H1N1) and in human Respiratory Syncytial Virus (RSV) using ProLectin-M..
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA), to initiate clinical trials of ProLectin-M for the treatment of mild to moderate COVID-19 in standard risk patients.
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients
BIXT announces the initiation of a clinical trial to treat Mild to Moderate COVID-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board
BIOXYTRAN announces Leslie Ajayi, MD as its interim Chief Medical Officer and Chief of the Medical Advisory Board. In this role Dr. Ajay will provide leadership and direction to the clinical operations, clinical affairs, clinical sciences, and drug safety. He will report to the CEO Dr David Platt and chair the Medical Advisory Board.
Bioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 Mutations
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001) / Complete elimination of most symptoms by day 7 / Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19
Bioxytran Interview at the Emerging Growth Conference
Bioxtran CCO Michael Sheikh will be discussing the medical and scientific communities’ reaction to the latest peer reviewed journal article on the Emerging Growth Conference on May 3, 2023 at 12:35 pm EST.
Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials
Long awaited Acelluar Oxygen Carrier BXT-25 has been successfully tested in animals.
Bioxytran Interview at the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
1. Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo(p=.001). // 2. Complete elimination of most symptoms by day 7. // 3. Galectin antagonist acts as an entry inhibitor for use in treatment of COVID-19
ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus
Activity in Influenza and Respiratory Syncytial Virus highlights the broad spectrum antiviral potential of ProLectin-M
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
The article highlighted 3 out of 5 polysaccharides that Dr. David Platt invented as therapies over his 30-year career in galectins. The article concluded that galectins shared a common pro-fibrotic function and that disease conditions like NASH, Idiopathic Pulmonary Fibrosis (IPF) and malignancies could benefit from targeting galectins as well as a diverse group of other disease states implicated by heightened galectin expression.
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
The top theory behind the pathogenesis of Long Covid is viral persistence6 or viral fragments. ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication competent viruses’ ability to infect other cells, but it also binds to spike protein fragments thought to be the cause of ongoing inflammation. 7
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization
BioxyTran announces that it has established an Indian subsidiary (Pharmalectin India Private Limited). The purpose of the subsidiary is to launch commercial product sales of ProLectin-M should the company receive Central Drugs Standard Control Organization (CDSCO) approval.
Bioxytran Interview at the Emerging Growth Conference
Bioxtran CMO Michael Sheikh will be presenting the latest clinical trial results on the Emerging Growth Conference on December 14, 2022 at 1:45pm EST. Investors are encouraged to preregister to ensure you are able to attend the conference and receive any updates that are released.
Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients
BOSTON, MASSACHUSETTS, December 8, 2022: BioxyTran Inc. announces the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients. The trial’s objective is to provide guidance for a 408 patient Phase III trial.
Bioxytran, Inc. Announces the Reinitiation of Coverage of Its Stock by Avise Analytics
Bioxytran is developing niche therapeutics in the crowded Covid-19 antiviral drug space, setting a new benchmark with 100% of patients in mild-to-moderate condition recovering by day 7 and 88% of patients by day 3. ProLectin-M may have significant safety, efficacy, and dosing advantages over currently marketed therapies in its class. The targeted virus types represent an addressable market of over 10 million patients and a multi-billion-dollar market.
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in medRxiv
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo
Bioxytran Interview at the Emerging Growth Conference - Wednesday August 17th, 2022 @ 12PM EST
Wednesday, August 17, 2022 12:00pm 12:30pm EST Discussion of Clinical Trial Results
Novel Carbohydrate Antiviral Drug Candidate Acts Through Galectin Inhibition to Block SARS-CoV-2 Coronavirus
NEW PRESS RELEASE! ProLectin-M, a New Class of Oral Antiviral Drug. ProLectin-M is an orally administered experimental new drug candidate that targets the Carbohydrate Binding Domain portion on the SARS-CoV-2, coronavirus.
Bioxytran Published A Surrogate Marker for ARDS and Stroke Patients
Journal article published specifies the use of the MDX Viewer as an early warning sign of negative oxygen balance for use in Acute Respiratory Deficiency Syndrome (ARDS).
Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
Announcing the launch of a new presentation detailing the expected mechanism of action between BXT-10 and COVID-19 in order to reduce the viral load.
Bioxytran Guest Speaker on Perfusionists Continuing Education Program Discussing Acute Respiratory Distress Syndrome and Ways to Combat COVID-19
Dr. David Platt has been invited to be a guest presenter on the perfusionist network which is a continuing education forum for perfusionists. The program is broadcast live on the PerfWeb, and all major social media platforms like Twitter, Facebook, LinkedIn and immediately available for rebroadcast from their YouTube channel.
Bioxytran Seeking Partners for Late Stage Treatment of Wuhan Coronavirus using BXT-25
BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the brain, heart, lungs, and other vital organs is announcing its intention to explore partnering with international drug companies looking to treat end stage Wuhan Coronavirus patients that have Acute Respiratory Distress Syndrome (ARDS). A majority of late stage coronavirus patients that end up with acute respiratory distress syndrome (ARDS) which has been commonly referred to as Severe Respiratory Distress Syndrome (SRDS) during this latest outbreak.
Bioxytran Unveiling Concept of a new Vital Sign at Targeting Mitochondria World Congress
The head of Bioxytran’s scientific advisory board, Professor Avraham Mayevsky, will be presenting his abstract titled “Monitoring of Patients’Mitochondrial Function and Tissue Metabolic Score (TMS) In Critical CareMedicine. A New Standard of Care?” at the Targeting Mitochondria World Congress2019 in Berlin, Germany on October 29th
Latest Nobel Prize Validates Bioxytran at the Forefront of Scientific Discovery
The Nobel Laureates identified a genetic switch called hypoxia-inducible factor (HIF) that determines how cells adapt when oxygen levels drop. When oxygen levels are low and HIF is activated cells reduce their metabolic rates; this is important for short-term survival, but extended anaerobic metabolism can result in cell death and also causes lactic acid accumulation that harms tissues and organs.
Bioxytran Inc. Appoints Two Investment Bankers from Westbury Group to Its Advisory Board
BioxyTran announced today that it has invited John Jensen and Dr. Patrick Huddie from the Westbury Group to join Bioxytran’s Advisory Board to provide insight into capital markets, strategic partnerships and licensing opportunities, particularly in relation to the company’s listing strategy.
Bioxytran Inc. Announces Appointment of Dr. Hana Chen-Walden to Scientific Advisory Board
BioxyTran Inc announced today that it has retained Dr. Hana Chen-Walden, MD, BIRA Diploma in Regulatory Affairs, to join Bioxytran’s Scientific Advisory Board to assist designing the clinical trial protocol the company’s for Bioxytran’s flagship drug, BXT-25.
Bioxytran Inc. Appoints Cynthia Ekberg Tsai to Company Advisory Board
BioxyTran Inc announced today that it has appointed Cynthia Ekberg Tsai to the company’s Advisory Board. Ms. Tsai will work with Bioxytran’s leadership to engage key opinion leaders, organizations, and global research institutions in collaborating with Bioxytran’s flagship drug, BXT-25.
Bioxytran Inc. Bolsters Advisory Board with Addition of Veteran Financial Advisor Jonathan Barkman
BIOXYTRAN, INC. (OTC: BIXT) announced today that it has retained Jonathan Barkman to join Bioxytran’s Advisory Board to assist in the critical capitalization process for Bioxytran’s flagship drug, BXT-25.
Avise Analytics Initiates Coverage on Bioxytran Inc.
BOSTON, MASSACHUSETTS, July 23, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that Avise Analytics, a leading equity research firm specializing in micro-cap and small-cap public companies research has initiated coverage on Bioxtytran, Inc.
Bioxytran Inc. Invited to New York Venture Summit
BOSTON, MASSACHUSETTS, July 09, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTC: BIXT), a developmental stage biotechnology company developing a pipeline of novel anti-necrosis drugs designed to treat stroke victims announced today that it was invited to attend the 19th annual New York Venture Summit, presented by youngStartup Ventures on July 9th and July 10th. The summit is being held at the Convene meeting center in New York City.
Bioxytran's Mdx Viewer Demonstrates Early Warning Signs of Brain Health During Cardiovascular Surgeries
BIOXYTRAN, INC. announced today that the American Journal of Cardiovascular and Thoracic Surgery published a peer reviewed article that validated animal models that showed the correlation between the surgical procedure and a new vital sign called the Tissue Metabolic Score (TMS).
Bioxytran Now Using Paradigm Changing Vital Sign That Can Measure Real-Time Tissue Oxygen Balance in Emergency Medicine
BIOXYTRAN, INC. announced today that the Journal of Emergency Medicine and Care published a peer-reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS).
Bioxytran, Inc. Announces Public Company Executive Steve Aust to Join Advisory Board
BIOXYTRAN, INC. announced today that it has retained Steve Aust to join Bioxytran’s Advisory Board. Mr. Aust will provide strategic planning to building awareness of Bioxytran’s technology with key opinion leaders.
go back

Sign up for
BioXyTran Updates

Site
Terms of Sale
Terms of Use
Privacy Policy
Careers
233 Needham Street
Suite 300
Newton, MA, 02464
617-454-1199
info@bioxytraninc.com
Follow us on Twitter
Follow us on Facebook
Follow us on Instagram
Follow us on LinkedIn
All statements and expressions are the sole opinion of the editor and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as "expects", "will", "anticipates", "estimates", "believes", or by statements indicating certain actions "may", "could", "should" or "might" occur.
© 2019 BioXyTran Inc.. All Rights Reserved